Which companies overlap with Beijing Pearl Biotechnology Limited Liability Company's portfolio?

Top competitors by shared drug class: Eli Lilly, Pfizer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/beijing-pearl-biotechnology-limited-liability-company.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Beijing Pearl Biotechnology Limited Liability Company — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Beijing Pearl Biotechnology Limited Liability Company pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
PLB1001	PLB1001	phase 3	Kinase inhibitor		Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Eli Lilly · 1 shared drug class
Pfizer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Beijing Pearl Biotechnology Limited Liability Company:

Cite this brief

Drug Landscape (2026). Beijing Pearl Biotechnology Limited Liability Company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/beijing-pearl-biotechnology-limited-liability-company. Accessed 2026-05-17.